Navigation Links
MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years
Date:7/23/2009

DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH.PK) (http://www.mitcanada.ca http://www.mitinvest.ca), "MIT" is pleased to announce that it has been granted a completely new, 8,000 square foot operation facility, as per "MIT China" requirements, from the "China Medical City" in Taizhou city for a period of 2 and half years.

The operation facility will harbor all the sub-assembly, final assembly and quality control of Agro-Jet and Med-Jet products to be sold to the Chinese market.

MIT China assembly operation is planned to start in September 2009.

Japanese patent

MIT is pleased to announce that it has obtained its first Japanese Patent from the Japanese Patent and Trademark Office for its Needle-Free Jet-Injector. Other similar international patents are pending. This first Japanese patent is another important achievement and recognition from a leading technological country like Japan. MIT will now expand even more into the world market. This technology offers a front-line means of prevention against pandemics, contributes to eliminate the possibility of both pre-injection contamination and post-injection cross-infection from needles/syringes, increases institutional sanitation, and protects human health.

Marketing and sales

MIT is actively promoting its MED-JET for human use for mass-inoculation. With the continuing outbreak of the "swine-flu" H1-N1 and the increased fear and awareness of the pandemic that could affect millions of people, we believe that Canada and the world market must use MIT's unique needle-free technology to deliver safely and effectively the vaccine to the world population.

Medical International Technology Inc. is pleased to continue providing a safe and effective means to help prevent the spread of deadly diseases to both humans and animals through the use of the Med-Jet(R) and Agro-Jet(R) needle-free injection system.

    Karim Menassa, President
    On Behalf of the Board of Directors        Tel: 514-339-9355

About Medical International Technology, Inc. MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.

The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology Inc. takes no obligation to update or correct forward-looking statements.


'/>"/>
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
7. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
10. Phylonix granted broad European patent for transplanting human cells into zebrafish
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
Breaking Medicine Technology: